Medical/Pharmaceuticals

Sciwind Biosciences Reports Positive Interim Results from Phase 1c/2a Clinical Trial of XW003 (Ecnoglutide) in Overweight and Obese Adult Volunteers in China

* Mean body weight loss of 9.6% and 9.0% in participants receiving 1.8 mg and 2.4 mg XW003 for 14 weeks, respectively * Up to 72.4% of participants achieved weight loss of at least 5% at week 14 * XW003 was safe and well tolerated with gastrointestinal side effects as the most commonly repor...

2022-08-09 08:00 3732

FRONTIER BIOTECHNOLOGIES ANNOUNCES POSITIVE PHASE 1 RESULTS OF ITS FIRST CORONAVIRUS MAIN PROTEASE (MPRO) SMALL MOLECULE INHIBITOR, LAYING FOUNDATION FOR THE TREATMENT OF ACUTE AND LONG COVID

* FB2001 (Bofutrelvir) is a Coronavirus Mpro inhibitor, which exhibited potent anti-SARS-CoV-2 activityin vitro and in vivo * Phase 1 results show FB2001 to be generally safe and well tolerated. No significant difference was observed between Chinese and American populations. Single-agent anti...

2022-08-09 00:00 4196

BGI Ranks No. 1 among APAC and China Life Science Corporations for Seven Consecutive Years: 2022 Nature Index Annual Tables Revealed

SHENZHEN, China, Aug. 8, 2022 /PRNewswire/ -- BGI has topped the Asia Pacific andChina life science corporate institution ranking table for the seventh year running, released in the 2022 Nature Index Annual Tables. With a 19 percent increase in its adjusted share metric, BGI ranked eighth among g...

2022-08-08 22:00 3200

Prominent Stanford University scientist and cellular reprogramming innovator will oversee all research for Turn Bio

Vittorio Sebastiano, globally recognized for pioneering science, expands his role at company he co-founded as it moves closer to clinical research MOUNTAIN VIEW, Calif., Aug. 8, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreata...

2022-08-08 20:00 4672

PNAS Published Preclinical Results of Harbour BioMed's Next-Generation Fully Human Heavy-chain Antibody Porustobart

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 8, 2022 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142) announced that the preclinical results of porustobart (HBM4003,or the HCAb 4003-2 in the research paper), a next-generation fully human heavy-chain antibody with a ...

2022-08-08 17:43 2750

Prenetics Launches Circle Snapshot, Simple At-home Blood Tests Using the World's First Push-Button and Painless Blood Collection Device

- Circle Snapshot, a patented, painless, at-home blood test with laboratory results delivered digitally.  - The test utilises a CE-certified blood collection device, which is a  proprietary micro-needle technology that draws capillary blood painlessly using a novel microfluidic extraction process....

2022-08-08 16:45 4475

The world's leading brand of fashionable colored masks officially launches on Amazon on August 8th from CSD, a professional disposable medical supplies manufacturer in Taiwan

TAIPEI, Aug. 8, 2022 /PRNewswire/ -- People dress according to mood, occasion, and necessity - and the mask, which inherently occupies half of the face, is an indispensable fashion accessory. On August 8th, COLO, a fashionable mask brand with colorful designs, will debut onAmazon

2022-08-08 13:04 2435

Xinhua Silk Road: E. China's Wuxi city steps up biomedical industry development

BEIJING, Aug. 8, 2022 /PRNewswire/ -- The 2022 Taihu Bay Future Healthcare Conference held Thursday in Wuxi City in eastChina's Jiangsu Province witnessed the launch of Wuxi Intellectual Property Protection Center with 52 biomedical projects contracted, involving a total of more than30 billion yu...

2022-08-08 12:24 4491

Qmed Asia launches Qmed GO "Mini Clinics" to Solve Rising Employee Healthcare Costs

Disrupting the medical landscape through an innovative internet-enabled clinical kiosk. KUALA LUMPUR, Malaysia, Aug. 8, 2022 /PRNewswire/ -- Qmed Asia  launched the Qmed GO at the recent Malaysia International Retail and Franchise (MIRF) Exhibition 2022 held at theKuala Lu...

2022-08-08 10:15 3739

BIO Asia-Taiwan 2022 concludes, marking another successful edition of the region's biggest bioindustry-focused conference and exhibition

Exhibition visitors surpass 100,000 people over 4 days BIO Asia–Taiwan success a testament to Taiwan's booming biotechnology industry TAIPEI, Aug. 8, 2022 /PRNewswire/ -- BIO Asia–Taiwan 2022, held at the TaiNEX 2 Exhibition Center, Nangang,Taipei, from 27-31 July, came to a successful conclusio...

2022-08-08 10:00 6115

BioDuro-Sundia and X-Chem enter partnership to launch DEL services in China for the discovery of new small molecule drugs

SHANGHAI, Aug. 8, 2022 /PRNewswire/ -- BioDuro-Sundia, an industry-leading drug discovery, development and commercial service CRDMO backed by Advent International, and X-Chem, a DEL technology pioneer in small molecule drug discovery, jointly announced the launch of DNA Encoded Compound Library (...

2022-08-08 09:06 4470

ImmVira's Brand New oHSV Product MVR-C5252 Targeting Malignant Glioma Obtained FDA's Orphan Drug Designation

SHENZHEN, China, Aug. 7, 2022 /PRNewswire/ -- On August 1, 2022, U.S. time, ImmVira's brand new oncolytic herpes simplex virus ("oHSV") product MVR-C5252 targeting Malignant Glioma has obtained Orphan Drug Designation ("ODD") from U.S. Food and Drug Administration ("FDA").

2022-08-08 08:30 2224

Ascletis Announces First Patient Dosed in the U.S. Phase I Clinical Trial of Oral PD-L1 Small Molecule Inhibitor Prodrug ASC61 for Treatment of Advanced Solid Tumors

--ASC61 is an in-house developed oral PD-L1 small molecule inhibitor prodrug that showed significant antitumor efficacy in preclinical studies as a single agent in multiple animal models --ASC61-A treatment induced secretion of IFNγ in a concentration dependent manner with an EC50 of 2.86 nM. Ma...

2022-08-08 08:10 3880

CStone presents updated results of a registrational study of sugemalimab in patients with stage III NSCLC via oral presentation at WCLC 2022

* GEMSTONE-301 study result was presented at IASLC 2022 World Conference on Lung Cancer. In addition, the leading Principal Investigator ProfessorYi-Long Wu was invited to highlight key data in a press conference * In the final progression-free survival analysis, sugemalimab showed sustained ...

2022-08-08 08:08 3752

Transcenta Announces the Appointment of Dr. Caroline Germa as Executive Vice President, Global Medicine Development and Chief Medical Officer

SUZHOU, China, Aug. 8, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics,announces the appointment of Dr. ...

2022-08-08 08:00 3711

Innovent Announces First Patient Dosed in Phase 1 Study of IBI324 (VEGF-A/Ang-2 Bispecific Antibody) in Patients with Diabetic Macular Edema

SAN FRANCISCO and SUZHOU, China, Aug. 8, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...

2022-08-08 08:00 4093

Telix and University of Queensland-led Consortium Awarded $5M Australian Research Council (ARC) Grant

MELBOURNE, Australia, Aug. 8, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has been jointly awarded a$4.8 million Australian Research Council (ARC) grant to establish a new Industrial Transformation Research Program (ITRP) Hub as part o...

2022-08-08 07:55 3693

Epigenic Therapeutics Raises $20 Million in Series Angel and Pre-A Funding to Advance Next Generation Gene Editing Therapy

SHANGHAI, Aug. 6, 2022 /PRNewswire/ -- Epigenic Therapeutics Co., Ltd., a frontier biotechnology company dedicated to developing next generation gene editing therapy utilizing regulation of epigenetic genome for wide variety of diseases, today announced it has secured$20 million in Series Angel a...

2022-08-07 07:00 4140

BGI's Global Life Science Research Leadership Recognized in 2022 Nature Index

SHENZHEN, China, Aug. 5, 2022 /PRNewswire/ -- BGI's leading global position in life science research has been recognized in the 2022 Nature Index. BGI rose two places to 8th in the world among corporate institutions for its contribution to life science research and was the only Chinese corporate ...

2022-08-05 22:18 5925

WeTrade Group Announced a Strategic Partnership with Jiqing Bio Company, to Exclusively Sell Monkeypox Test Kits and Antigen Tests

BEIJING, Aug. 5, 2022 /PRNewswire/ -- On 5th August, WeTrade Group Inc. ("Wetrade" or the "Company") (NASDAQ: WETG), an emerging growth company engaged in the business of providing software-as-a-services (SAAS) and cloud intelligent systems for micro-businesses, today announced a strategic partn...

2022-08-05 21:10 5583
1 ... 533534535536537538539 ... 645